Version May 2024
| Regimen | Number of patients* | Tumor response rate (%) | Median progression-free survival (months) | Median overall survival (months) | Author; year |
| Prospective studies | |||||
| Chlorozotocin | 33 | 30¶ | 17 | 18.0 | Moertel C; 1992 |
| Fluorouracil plus streptozocin | 33 | 45¶ | 14 | 16.8 | |
| Doxorubicin plus streptozocin | 36 | 69¶ | 18 | 26.4 | |
| Dacarbazine (DTIC) | 50 | 34 | NR | 19.3 | Ramanathan R; 2001 |
| Temozolomide plus thalidomide | 11 | 45 | NR | NR | Kulke M; 2006 |
| Temozolomide plus bevacizumab | 15 | 33 | 14.3 | 41.7 | Chan JA; 2012 |
| Temozolomide plus everolimus | 40 | 40 | 15.4 | NR | Chan JA; 2013 |
| Temozolomide plus capecitabine | 72 | 33 | 22.7 | 58.7 | Kunz PL; 2022 |
| Temozolomide | 72 | 28 | 14.4 | 53.8 | |
| Retrospective series | |||||
| Steptozocin plus doxorubicin plus fluorouracil | 84Δ | 39 | 18 | 37 | Kouvaraki M; 2004 |
| Temozolomide (diverse regimens) | 53 | 34 | 13.6 | 35.3 | Kulke M; 2009 |
| Streptozocin plus fluorouracil | 96 | 43 | 19.4 | 54.8 | Dilz LM; 2015 |
| Temozolomide (single agent) | 12 | 8 | NR | NR | Ekeblad S; 2007 |
| Temozolomide plus capecitabine | 30 | 70 | 18 | NR | Strosberg J; 2011 |
NR: not reported.
* Number of patients evaluable for efficacy endpoints.
¶ Combined biochemical and radiologic response rate.
Δ Includes patients with locally advanced disease.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
